scholarly journals Association of polymorphisms in angiotensin and aldosterone synthase genes of the renin–angiotensin–aldosterone system with high-altitude pulmonary edema

2011 ◽  
Vol 13 (1) ◽  
pp. 155-160 ◽  
Author(s):  
Swati Srivastava ◽  
Shuchi Bhagi ◽  
Babita Kumari ◽  
Khem Chandra ◽  
Soma Sarkar ◽  
...  

Studies on different populations have suggested variability in individual susceptibility to altitude sickness depending on genetic makeup. The renin–angiotensin–aldosterone system (RAAS) pathway plays a key role in regulation of vascular tone and circulatory homeostasis. The present study was undertaken to investigate the possible association of the RAAS in the development of high-altitude pulmonary edema (HAPE) in lowlanders exposed to high altitude. Three categories of subjects were selected: individuals who developed HAPE on acute induction to high altitude ( HAPE); individuals tolerant to high-altitude exposure who showed no symptoms of HAPE (resistant controls; rCON); and natives of high altitude ( HAN). Genetic variants in the genes of the RAAS such as renin ( REN), angiotensin ( AGT), angiotensin-converting enzyme ( ACE), aldosterone synthase ( CYP11B2) and angiotensin II receptor type 1 ( AGTR1) have been investigated. The T174M polymorphism in AGT showed a significant difference in HAPE and HAN and also HAN and controls. Also, genotyping in the CYP11B2 T-344C promoter region resulted in a significant difference between HAPE and HAN both at genotypic and allelic levels. The genotypic difference was statistically insignificant for the AGTR1 A1166C 3’ UTR. The present investigation demonstrates a possible association between the polymorphisms existing in the RAAS pathway T174M and CYP11B2 C-344T and sensitivity of an individual to develop HAPE. The results also indicate the existence of ethnic variation between the HAN and the other two groups comprising lowlanders.

Oncotarget ◽  
2016 ◽  
Vol 7 (47) ◽  
pp. 77117-77123 ◽  
Author(s):  
Tianbo Jin ◽  
Yongchao Ren ◽  
Xikai Zhu ◽  
Xun Li ◽  
Yongri Ouyang ◽  
...  

CHEST Journal ◽  
2004 ◽  
Vol 126 (3) ◽  
pp. 825-830 ◽  
Author(s):  
Junichi Hotta ◽  
Masayuki Hanaoka ◽  
Yunden Droma ◽  
Yoshihiko Katsuyama ◽  
Masao Ota ◽  
...  

Author(s):  
Davide Ventura ◽  
Amy L Carr ◽  
R Duane Davis ◽  
Scott Silvestry ◽  
Linda Bogar ◽  
...  

Abstract It has been established SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2), a membrane-bound regulatory peptide, for host cell entry. Renin-angiotensin-aldosterone system (RAAS) inhibitors have been reported to increase ACE2 in type 2 pneumocytes pulmonary tissue. Controversy exists for the continuation of ACE inhibitors, angiotensin II receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) in the current pandemic. ACE2 serves as regulatory enzyme in maintaining homeostasis between proinflammatory Angiotensin II and anti-inflammatory Angiotensin 1,7 peptides. Derangements in these peptides are associated with cardiovascular disease and are implicated in the progression of acute respiratory distress syndrome (ARDS). Augmentation of the ACE2/Ang1,7 axis represent a critical target in the supportive management of COVID-19 associated lung disease. Observational data describing the use of RAAS inhibitors in the setting of SARS-CoV-2 have not borne signals of harm to date. However, equipoise persists requiring an analysis of novel agents including recombinant human-ACE2 and existing RAAS inhibitors while balancing ongoing controversies associated with increased coronavirus infectivity and virulence.


Sign in / Sign up

Export Citation Format

Share Document